https://www.selleckchem.com/pr....oducts/etomoxir-na-s
4 [0.5] vs. 2.2 [0.6] mmol/L; P 0.0001). Physical Function reported by patients on the Kidney Disease and Quality of Life - Physical Function Domain, a measure that includes items related to walking, stair climbing, carrying groceries and other activities improved significantly in women randomized to veverimer vs placebo (+ 13.2 vs. -5.2, respectively, P 0.0031). Objectively measured performance time on the repeated chair stand test also improved significantly in the veverimer group vs. placebo (P = 0.0002). Veverimer
Like
Comment
Share
